ATE274512T1 - Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten - Google Patents
Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonistenInfo
- Publication number
- ATE274512T1 ATE274512T1 AT00906324T AT00906324T ATE274512T1 AT E274512 T1 ATE274512 T1 AT E274512T1 AT 00906324 T AT00906324 T AT 00906324T AT 00906324 T AT00906324 T AT 00906324T AT E274512 T1 ATE274512 T1 AT E274512T1
- Authority
- AT
- Austria
- Prior art keywords
- phenylthioureas
- receptor antagonists
- orexin receptor
- receptors
- phenyl ureas
- Prior art date
Links
- 229940123730 Orexin receptor antagonist Drugs 0.000 title 1
- -1 PHENYL UREAS Chemical class 0.000 title 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 101000598921 Homo sapiens Orexin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical class NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 abstract 1
- 102000008834 Orexin receptor Human genes 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9903266.6A GB9903266D0 (en) | 1999-02-12 | 1999-02-12 | Compounds |
| GBGB9926430.1A GB9926430D0 (en) | 1999-11-08 | 1999-11-08 | Compounds |
| PCT/EP2000/001150 WO2000047577A1 (en) | 1999-02-12 | 2000-02-10 | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE274512T1 true ATE274512T1 (de) | 2004-09-15 |
Family
ID=26315129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00906324T ATE274512T1 (de) | 1999-02-12 | 2000-02-10 | Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6699879B1 (de) |
| EP (1) | EP1150977B1 (de) |
| JP (1) | JP2002536445A (de) |
| AT (1) | ATE274512T1 (de) |
| AU (1) | AU2804400A (de) |
| DE (1) | DE60013250T2 (de) |
| ES (1) | ES2226785T3 (de) |
| WO (1) | WO2000047577A1 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| EP1140840B1 (de) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2298311B1 (de) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| EP1199306B1 (de) * | 1999-07-26 | 2005-12-07 | Banyu Pharmaceutical Co., Ltd. | Biaryl-harnstoff-derivate |
| US20040029928A1 (en) * | 2000-08-31 | 2004-02-12 | Terukage Hirata | Novel propenohydroxamic acid derivatives |
| EP1353918B1 (de) * | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholinderivate als antagonisten an orexinrezeptoren |
| ES2283543T3 (es) * | 2001-04-20 | 2007-11-01 | Bayer Pharmaceuticals Corporation | Inhibicion de raf kinasa usando quinolil-, isoquinolil- o piridil ureas. |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| BR0209334A (pt) | 2001-05-05 | 2004-06-15 | Smithkline Beecham Plc | Aminas n-aroil cìclicas |
| EP1437344A4 (de) * | 2001-09-28 | 2006-09-20 | Takeda Pharmaceutical | Benzolderivate, verfahren zu deren herstellung und deren verwendung |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| JP4498922B2 (ja) | 2002-07-09 | 2010-07-07 | アクテリオン ファーマシューティカルズ リミテッド | ７，８，９，１０−テトラヒドロ−６Ｈ−アゼピノ、６，７，８，９−テトラヒドロ−ピリドおよび２，３−ジヒドロ−２Ｈ−ピロロ［２，１−ｂ］−キナゾリノン誘導体 |
| KR20050043967A (ko) * | 2002-09-17 | 2005-05-11 | 액테리온 파마슈티칼 리미티드 | 1-피리딘-4-일-요소 유도체 |
| NZ538749A (en) * | 2002-10-11 | 2006-11-30 | Actelion Pharmaceuticals Ltd | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
| GB0225944D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| JP2006521345A (ja) * | 2003-03-28 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 |
| ATE383345T1 (de) | 2003-04-28 | 2008-01-15 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. |
| EP1636585B2 (de) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-harnstoffe mit kinasehemmender wirkung |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| RU2378257C2 (ru) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
| US20060178307A1 (en) * | 2005-01-26 | 2006-08-10 | The Regents Of The University Of California | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor |
| US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| EP1928843A1 (de) * | 2005-08-22 | 2008-06-11 | Amgen, Inc | Bis-arylharnstoffverbindungen zur behandlung von durch proteinkinase vemittelten krankheiten |
| FR2896799B1 (fr) * | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| EP2049110B1 (de) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Verbrückte diazepanorexin-rezeptorantagonisten |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| JP2010513557A (ja) * | 2006-12-20 | 2010-04-30 | アボット・ラボラトリーズ | 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物 |
| WO2008143856A1 (en) | 2007-05-18 | 2008-11-27 | Merck & Co., Inc. | Oxo bridged diazepan orexin receptor antagonists |
| HRP20120240T1 (hr) | 2007-05-23 | 2012-04-30 | Merck Sharp & Dohme Corp. | Piridil piperidin antagonisti receptora za oreksin |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| ES2418457T3 (es) * | 2008-04-24 | 2013-08-13 | Abbott Gmbh & Co. Kg | Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3) |
| EP2161266A1 (de) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuranderivate als Orexin-Rezeptorantagonisten |
| KR20110091581A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도 |
| CN102459229A (zh) | 2009-04-24 | 2012-05-16 | 葛兰素集团有限公司 | 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷 |
| US20120149711A1 (en) | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| EP2470523A1 (de) | 2009-08-24 | 2012-07-04 | Glaxo Group Limited | 5-methyl-piperidinderivate als orexinrezeptor-antagonisten zur behandlung von schlafstörungen |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| WO2011138266A1 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indolizine and imidazopyridine derivatives as orexin receptor antagonists |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| US20160250224A1 (en) * | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CN106029647A (zh) * | 2013-12-20 | 2016-10-12 | 拜耳制药股份公司 | 葡萄糖转运抑制剂 |
| TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
| WO2016075134A1 (en) * | 2014-11-12 | 2016-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| EP3454857A1 (de) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und pharmazeutische zusammensetzungen zur behandlung entzündlicher augenkrankheiten |
| MA56193A (fr) * | 2019-06-14 | 2022-04-20 | Ifm Due Inc | Composés et compositions pour traiter des états associés à une activité de sting |
| JP2024502474A (ja) | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物 |
| CN114656406B (zh) * | 2022-01-25 | 2023-09-05 | 阿里生物新材料（常州）有限公司 | 一种2-氟代嘧啶-4-羧酸的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9302275D0 (en) * | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
| US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| ZA96497B (en) * | 1996-01-23 | 1996-08-13 | Bnfl Fluorchem Ltd | Halogenated compounds |
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| AU7933098A (en) | 1997-06-25 | 1999-01-04 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amidrazone derivatives having antifungal activity |
| AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| US6083944A (en) | 1997-10-07 | 2000-07-04 | Cephalon, Inc. | Quinoline-containing α-ketoamide cysteine and serine protease inhibitors |
| AU2108099A (en) * | 1998-01-30 | 1999-08-16 | Procept, Inc. | Immunosuppressive agents |
-
2000
- 2000-02-10 DE DE60013250T patent/DE60013250T2/de not_active Expired - Fee Related
- 2000-02-10 EP EP00906324A patent/EP1150977B1/de not_active Expired - Lifetime
- 2000-02-10 AU AU28044/00A patent/AU2804400A/en not_active Abandoned
- 2000-02-10 US US09/913,236 patent/US6699879B1/en not_active Expired - Fee Related
- 2000-02-10 AT AT00906324T patent/ATE274512T1/de not_active IP Right Cessation
- 2000-02-10 WO PCT/EP2000/001150 patent/WO2000047577A1/en not_active Ceased
- 2000-02-10 JP JP2000598497A patent/JP2002536445A/ja not_active Withdrawn
- 2000-02-10 ES ES00906324T patent/ES2226785T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002536445A (ja) | 2002-10-29 |
| US6699879B1 (en) | 2004-03-02 |
| DE60013250T2 (de) | 2005-09-08 |
| WO2000047577A1 (en) | 2000-08-17 |
| AU2804400A (en) | 2000-08-29 |
| ES2226785T3 (es) | 2005-04-01 |
| DE60013250D1 (en) | 2004-09-30 |
| EP1150977B1 (de) | 2004-08-25 |
| EP1150977A1 (de) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60013250D1 (en) | Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| DE60140860D1 (de) | 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren | |
| DE69818831D1 (de) | Indolderivate als mcp-1 rezeptor antagonisten | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
| HUP0202636A2 (hu) | Alkilén-diamin-csoporttal helyettesített heterogyűrűs vegyületek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
| BR0316169A (pt) | Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese | |
| TR200100694T2 (tr) | Opioid alıcı aktivitesine sahip 4,4-Biarilpiperidin türevleri | |
| HUP0401984A2 (hu) | A 4. tipusú foszfodiészteráz enzim aktivitását gátló inhibitorok alkalmazása gyógyszerkészítmények előállítására és más hatóanyagokkal alkotott kombinációik | |
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| ATE384058T1 (de) | Thiazolderivate | |
| BR0215151A (pt) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| BR0311952A (pt) | Novos compostos úteis para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc | |
| NO20054848L (no) | Substituerte p-diaminobenzenderivater | |
| TW200519101A (en) | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| DE60308699D1 (en) | 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren | |
| ATE370147T1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
| NO20052699L (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser. | |
| DE60037888D1 (de) | Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| DE502004007387D1 (de) | Triazolverbindungen und ihre therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |